In-depth clinical and biological exploration of DNA damage immune response as a biomarker for oxaliplatin use in colorectal cancer

In-depth clinical and biological exploration of DNA damage immune response as a biomarker for oxaliplatin use in colorectal cancer

<p><strong>Purpose:</strong> The DNA damage immune response (DDIR) assay was developed in breast cancer based on biology associated with deficiencies in homologous recombination and Fanconi anemia pathways. A positive DDIR call identifies patients likely to respond to platinum-base...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Malla, SB, Fisher, DJ, Domingo, E, Blake, A, Hassanieh, S, Redmond, KL, Richman, SD, Youdell, M, Walker, SM, Logan, GE, Chatzipli, A, Amirkhah, R, Humphries, MP, Craig, SG, McDermott, U, Seymour, MT, Morton, DG, Quirke, P, West, NP, Salto-Tellez, M, Kennedy, RD, Johnston, PG, Tomlinson, I, Koelzer, VH, Campo, L, Kaplan, RS, Longley, DB, Lawler, M, Maughan, TS, Brown, LC, Dunne, PD
Beste egile batzuk: S:CORT consortium
Formatua: Journal article
Hizkuntza:English
Argitaratua: American Association for Cancer Research 2020

Antzeko izenburuak